Protagonist Therapeutics Inc. (NASDAQ: PTGX) announced that one-year Phase 3 results for ICOTYDE (icotrokinra) were presented at the 2026 American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE